Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology
JF Gomes Marin, RF Nunes, AM Coutinho… - Radiographics, 2020 - pubs.rsna.org
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications
Interest in the use of radionuclides for treatment of various diseases has a long history and
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands
K Sjögreen Gleisner, N Chouin, PM Gabina… - European journal of …, 2022 - Springer
The purpose of the EANM Dosimetry Committee is to provide recommendations and
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals …
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, R Baum… - European journal of …, 2019 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine …
M. Falconi a B. Eriksson b G. Kaltsas c DK Bartsch d J. Capdevila e M. Caplin f B. Kos-Kudla
g D. Kwekkeboom h G. Rindi i G. Klöppel j N. Reed k R. Kianmanesh l RT Jensen m all other …
g D. Kwekkeboom h G. Rindi i G. Klöppel j N. Reed k R. Kianmanesh l RT Jensen m all other …
177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy
The objective of this study was to analyze the safety and efficacy of the 177Lu-labeled
DOTAGA-based prostate-specific membrane antigen (PSMA) ligand 177Lu-DOTAGA-(Iy) fk …
DOTAGA-based prostate-specific membrane antigen (PSMA) ligand 177Lu-DOTAGA-(Iy) fk …
ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin …
The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and …
SM Sadowski, V Neychev, C Millo, J Shih… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) are increasing in
incidence, and accurate staging is important for selecting the appropriate treatment. 68Ga …
incidence, and accurate staging is important for selecting the appropriate treatment. 68Ga …
Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
A Delker, WP Fendler, C Kratochwil… - European journal of …, 2016 - Springer
Purpose Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy
(RLT) with limited side effects. Our aim was to perform image-based absorbed dose …
(RLT) with limited side effects. Our aim was to perform image-based absorbed dose …
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …